IL145487A0 - Apomorphine and sildenafil composition - Google Patents
Apomorphine and sildenafil compositionInfo
- Publication number
- IL145487A0 IL145487A0 IL14548700A IL14548700A IL145487A0 IL 145487 A0 IL145487 A0 IL 145487A0 IL 14548700 A IL14548700 A IL 14548700A IL 14548700 A IL14548700 A IL 14548700A IL 145487 A0 IL145487 A0 IL 145487A0
- Authority
- IL
- Israel
- Prior art keywords
- apomorphine
- sildenafil
- administered
- treatment
- sildenafil composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/270,035 US6087362A (en) | 1999-03-16 | 1999-03-16 | Apomorphine and sildenafil composition |
PCT/US2000/006654 WO2000054774A1 (fr) | 1999-03-16 | 2000-03-14 | Composition d'apomorphine et de sildenafil |
Publications (1)
Publication Number | Publication Date |
---|---|
IL145487A0 true IL145487A0 (en) | 2002-06-30 |
Family
ID=23029614
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL14548700A IL145487A0 (en) | 1999-03-16 | 2000-03-14 | Apomorphine and sildenafil composition |
Country Status (21)
Country | Link |
---|---|
US (1) | US6087362A (fr) |
EP (1) | EP1173178B1 (fr) |
JP (1) | JP2002539163A (fr) |
CN (1) | CN1350454A (fr) |
AT (1) | ATE302003T1 (fr) |
AU (1) | AU3744500A (fr) |
BR (1) | BR0009016A (fr) |
CA (1) | CA2367605A1 (fr) |
CZ (1) | CZ20013344A3 (fr) |
DE (1) | DE60022021T2 (fr) |
DK (1) | DK1173178T3 (fr) |
ES (1) | ES2244418T3 (fr) |
HU (1) | HUP0200549A3 (fr) |
IL (1) | IL145487A0 (fr) |
MX (1) | MXPA01009332A (fr) |
NO (1) | NO324511B1 (fr) |
NZ (1) | NZ514464A (fr) |
PL (1) | PL350313A1 (fr) |
PT (1) | PT1173178E (fr) |
WO (1) | WO2000054774A1 (fr) |
ZA (1) | ZA200107920B (fr) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040063719A1 (en) * | 1998-08-26 | 2004-04-01 | Queen's University At Kingston | Combination therapy using antihypertensive agents and endothelin antagonists |
US6428769B1 (en) * | 1999-05-04 | 2002-08-06 | Aradigm Corporation | Acute testosterone administration |
US20020013327A1 (en) * | 2000-04-18 | 2002-01-31 | Lee Andrew G. | Compositions and methods for treating female sexual dysfunction |
US20030139384A1 (en) * | 2000-08-30 | 2003-07-24 | Dudley Robert E. | Method for treating erectile dysfunction and increasing libido in men |
US6503894B1 (en) | 2000-08-30 | 2003-01-07 | Unimed Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating hypogonadism |
PL205279B1 (pl) * | 2000-08-30 | 2010-03-31 | Besins International Lab | Zastosowanie żelu hydroalkoholowego zawierającego testosteron i zestaw do leczenia zaburzenia erekcji |
US6821978B2 (en) * | 2000-09-19 | 2004-11-23 | Schering Corporation | Xanthine phosphodiesterase V inhibitors |
US20020091129A1 (en) * | 2000-11-20 | 2002-07-11 | Mitradev Boolell | Treatment of premature ejaculation |
EP1365740A1 (fr) * | 2001-02-08 | 2003-12-03 | Pharmacia Corporation | Medicament a action rapide pour le traitement de dysfonctionnements sexuels |
ES2180446B1 (es) * | 2001-07-02 | 2004-01-16 | Esteve Labor Dr | Empleo de derivados de acidos 2,5-dihidroxibencenosulfonicos en la elaboracion de un medicamento para potenciar el efecto de otros farmacos en el tratamiento de la disfuncion erectil. |
US20030044458A1 (en) * | 2001-08-06 | 2003-03-06 | Curtis Wright | Oral dosage form comprising a therapeutic agent and an adverse-effect agent |
JP4450365B2 (ja) * | 2001-08-28 | 2010-04-14 | シェーリング コーポレイション | 多環式グアニンホスホジエステラーゼv阻害剤 |
US20030114469A1 (en) * | 2001-09-27 | 2003-06-19 | Cohen David Saul | Combinations |
US20030216407A1 (en) * | 2002-01-31 | 2003-11-20 | Pfizer Inc. | Use of PDE5 inhibitors in the treatment of scarring |
BR0308567A (pt) * | 2002-03-19 | 2007-01-09 | Michael Holick | derivados de glicosìdeo e glicosìdeo de ortoéster de apomorfina, análogos, e seus usos |
US8821915B2 (en) | 2002-08-09 | 2014-09-02 | Veroscience, Llc | Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders |
US7037257B1 (en) * | 2002-08-22 | 2006-05-02 | Koenig J Frank | Erectile dysfuction treatments comprising momentary vacuum therapy alone or with medications |
TWI330529B (en) * | 2003-01-13 | 2010-09-21 | Horphag Res Luxembourg Holding Sa | A preparation for improving sperm quality or fertility,a kit comprising the same and uses thereof |
GB0304636D0 (en) * | 2003-02-28 | 2003-04-02 | Britannia Pharmaceuticals Ltd | Pharmaceutical composition for nasal delivery |
US7306812B2 (en) * | 2003-05-09 | 2007-12-11 | Cephalon, Inc. | Dissolvable backing layer for use with a transmucosal delivery device |
US7276246B2 (en) * | 2003-05-09 | 2007-10-02 | Cephalon, Inc. | Dissolvable backing layer for use with a transmucosal delivery device |
DE10325813B4 (de) * | 2003-06-06 | 2007-12-20 | Universitätsklinikum Freiburg | Prophylaxe und/oder Therapie bei der portalen Hypertonie |
MXPA06013133A (es) * | 2004-05-11 | 2007-05-23 | Emotional Brain Bv | Formulaciones farmaceuticas y usos de las mismas en el tratamiento de la disfuncion sexual femenina. |
ES2553101T3 (es) * | 2004-10-20 | 2015-12-04 | Endorecherche Inc. | Precursor de esteroides sexuales en combinación con un modulador selectivo del receptor de estrógenos para la prevención y tratamiento de atrofia vaginal en mujeres postmenopáusicas |
ZA200803087B (en) | 2005-10-12 | 2009-11-25 | Unimed Pharmaceuticals Llc | Improved testosterone gel and method of use |
CA2677691C (fr) * | 2007-02-12 | 2012-07-31 | David Bar-Or | Reduction des effets secondaires du tramadol |
PL2120570T3 (pl) * | 2007-02-12 | 2012-10-31 | Vyrix Pharmaceuticals Inc | Leczenie współwystępującego przedwczesnego wytrysku i zaburzenia wzwodu prącia |
US20100035886A1 (en) | 2007-06-21 | 2010-02-11 | Veroscience, Llc | Parenteral formulations of dopamine agonists |
US8741918B2 (en) | 2007-06-21 | 2014-06-03 | Veroscience Llc | Parenteral formulations of dopamine agonists |
GB0715285D0 (en) * | 2007-08-06 | 2007-09-12 | Britannia Pharmaceuticals Ltd | Improvements in or relating to powdered medicaments for nasal delivery |
US8268806B2 (en) | 2007-08-10 | 2012-09-18 | Endorecherche, Inc. | Pharmaceutical compositions |
RU2547939C2 (ru) * | 2007-12-26 | 2015-04-10 | Биотест Аг | Иммуноконъюгаты, направленные на cd138, и их применение |
WO2009080829A1 (fr) * | 2007-12-26 | 2009-07-02 | Biotest Ag | Agents ciblant cd138 et leurs applications |
BRPI0821417A2 (pt) * | 2007-12-26 | 2015-06-16 | Biotest Ag | Método para diminuir a adesão de células de estroma a células tumorais que expressam cd138 em células tumorais de um indivíduo em necessidade do mesmo |
AR069979A1 (es) * | 2007-12-26 | 2010-03-03 | Biotest Ag | Metodo para disminuir los efectos secundarios citotoxicos y mejorar la eficacia de los inmunoconjugados |
US20090246298A1 (en) * | 2008-03-31 | 2009-10-01 | Ceola P. Steele | Viagra |
US20100184722A1 (en) * | 2008-12-19 | 2010-07-22 | Shimoda Biotech (Pty) Ltd | Inclusion complexes of alpha-cyclodextrin and sildenafil salt |
WO2010128087A2 (fr) * | 2009-05-06 | 2010-11-11 | Biotest Ag | Utilisations d'immunoconjugués ciblant l'antigène cd138 |
US9352025B2 (en) | 2009-06-05 | 2016-05-31 | Veroscience Llc | Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders |
DK2952191T3 (en) | 2009-06-12 | 2018-12-10 | Sunovion Pharmaceuticals Inc | Sublingual apomorphine |
WO2012000634A1 (fr) | 2010-06-29 | 2012-01-05 | Georg Bambach | Composition pharmaceutique pour le traitement de dysfonction érectile |
TWI462739B (zh) | 2010-11-02 | 2014-12-01 | Univ Kaohsiung Medical | Sildenafil-同族物四級銨哌嗪鹽類之製備及醫療用途 |
CA3115378A1 (fr) | 2010-12-16 | 2012-06-21 | Sunovion Pharmaceuticals Inc. | Films sublinguaux comprenant de l'apomorphine et une base organique |
RU2632108C2 (ru) | 2011-12-08 | 2017-10-02 | Биотест Аг | Применения иммуноконъюгатов, мишенью которых является cd138 |
EP3285771A4 (fr) | 2015-04-21 | 2018-12-05 | Sunovion Pharmaceuticals Inc. | Méthodes de traitement de la maladie de parkinson par l'administration d'apomorphine à une muqueuse orale |
WO2017168174A1 (fr) | 2016-04-02 | 2017-10-05 | N4 Pharma Uk Limited | Nouvelles formes pharmaceutiques du sildénafil |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5256652A (en) * | 1987-11-12 | 1993-10-26 | Pharmedic Co. | Topical compositions and methods for treatment of male impotence |
EP0978282B1 (fr) * | 1994-04-22 | 2005-12-14 | Pentech Pharmaceuticals, Inc. | Composition sublinguale d'apomorphine pour diagnostiquer l'impuissance fonctionnelle |
GB9612514D0 (en) * | 1996-06-14 | 1996-08-14 | Pfizer Ltd | Novel process |
EP0996447B1 (fr) * | 1997-05-19 | 2006-07-19 | Zonagen, Inc. | Therapie combinatoire permettant de moduler la reponse sexuelle chez un patient |
US6037346A (en) * | 1997-10-28 | 2000-03-14 | Vivus, Inc. | Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction |
US6200591B1 (en) * | 1998-06-25 | 2001-03-13 | Anwar A. Hussain | Method of administration of sildenafil to produce instantaneous response for the treatment of erectile dysfunction |
-
1999
- 1999-03-16 US US09/270,035 patent/US6087362A/en not_active Expired - Fee Related
-
2000
- 2000-03-14 MX MXPA01009332A patent/MXPA01009332A/es active IP Right Grant
- 2000-03-14 JP JP2000604850A patent/JP2002539163A/ja active Pending
- 2000-03-14 AU AU37445/00A patent/AU3744500A/en not_active Abandoned
- 2000-03-14 CZ CZ20013344A patent/CZ20013344A3/cs unknown
- 2000-03-14 CA CA002367605A patent/CA2367605A1/fr not_active Abandoned
- 2000-03-14 PL PL00350313A patent/PL350313A1/xx not_active Application Discontinuation
- 2000-03-14 DE DE60022021T patent/DE60022021T2/de not_active Expired - Fee Related
- 2000-03-14 HU HU0200549A patent/HUP0200549A3/hu unknown
- 2000-03-14 DK DK00916324T patent/DK1173178T3/da active
- 2000-03-14 BR BR0009016-6A patent/BR0009016A/pt not_active Application Discontinuation
- 2000-03-14 NZ NZ514464A patent/NZ514464A/xx unknown
- 2000-03-14 WO PCT/US2000/006654 patent/WO2000054774A1/fr active IP Right Grant
- 2000-03-14 ES ES00916324T patent/ES2244418T3/es not_active Expired - Lifetime
- 2000-03-14 CN CN00807580A patent/CN1350454A/zh active Pending
- 2000-03-14 IL IL14548700A patent/IL145487A0/xx unknown
- 2000-03-14 EP EP00916324A patent/EP1173178B1/fr not_active Expired - Lifetime
- 2000-03-14 PT PT00916324T patent/PT1173178E/pt unknown
- 2000-03-14 AT AT00916324T patent/ATE302003T1/de not_active IP Right Cessation
-
2001
- 2001-09-17 NO NO20014519A patent/NO324511B1/no unknown
- 2001-09-26 ZA ZA200107920A patent/ZA200107920B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
ZA200107920B (en) | 2003-03-26 |
ATE302003T1 (de) | 2005-09-15 |
PT1173178E (pt) | 2005-11-30 |
BR0009016A (pt) | 2002-04-16 |
WO2000054774A1 (fr) | 2000-09-21 |
DE60022021T2 (de) | 2006-06-08 |
CA2367605A1 (fr) | 2000-09-21 |
DK1173178T3 (da) | 2005-11-07 |
NO20014519L (no) | 2001-10-25 |
AU3744500A (en) | 2000-10-04 |
CZ20013344A3 (cs) | 2002-08-14 |
ES2244418T3 (es) | 2005-12-16 |
EP1173178A1 (fr) | 2002-01-23 |
CN1350454A (zh) | 2002-05-22 |
US6087362A (en) | 2000-07-11 |
PL350313A1 (en) | 2002-12-02 |
NO324511B1 (no) | 2007-11-05 |
JP2002539163A (ja) | 2002-11-19 |
HUP0200549A2 (hu) | 2002-07-29 |
DE60022021D1 (de) | 2005-09-22 |
NZ514464A (en) | 2004-01-30 |
MXPA01009332A (es) | 2002-06-21 |
EP1173178A4 (fr) | 2002-09-04 |
EP1173178B1 (fr) | 2005-08-17 |
NO20014519D0 (no) | 2001-09-17 |
HUP0200549A3 (en) | 2004-07-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL350313A1 (en) | Apomorphine and sildenafil composition | |
NZ540385A (en) | Use of 1-oxo-2-(2, 6-dioxopiperidin-3-yl)-4-methylisoindoline in the manufacture of a medicamnent for treatment of brain cancer | |
HK1177901A1 (en) | Treatment of t-cell lymphoma using 10-propargyl-10-deazaaminopterin 10--10- t | |
HRP20080598T3 (en) | Combination of et-743 with 5-fluorouracil pro-drugs for the treatment of cancer | |
CA2582452A1 (fr) | Doxorubicine liposomale pegylee en combinaison avec l'ecteinascidine 743 | |
NZ517038A (en) | Use of serotonin reuptake inihibitor in medicaments for treating sexual dysfunction | |
NZ591525A (en) | Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin | |
HK1077215A1 (en) | A pharmaceutical composition for treatment of acute myocardial infarction | |
CA2368614A1 (fr) | Traitement du cancer ameliore avec le temozolomide | |
JP2002540148A5 (fr) | ||
FI20011464A0 (fi) | Yhdistelmäterapia sydämen vajaatoiminnan hoitoon | |
CA2516458A1 (fr) | Utilisation de composes de kahalalide pour la fabrication d'un medicament pour le traitement de psoriasis | |
MXPA02009603A (es) | Terapias de dosis divididas con actividad de deterioro vascular. | |
AR109456A2 (es) | Uso de et743 para la preparación de un medicamento para el tratamiento de un paciente humano afectado por cáncer mediante terapia de combinación | |
PT1265629E (pt) | Utilizacao da hormona de crescimento em dose baixa | |
RU2002129097A (ru) | Комбинированные терапии с использованием активности, повреждающей сосуды | |
BRPI0503488A (pt) | agente de tratamento para sìndrome de intestino irritável com diarréia predominante |